Citryll Demonstrates a Broader Therapeutic Potential for CIT-013 in the Treatment of Inflammatory Disorders

Breakthrough study published in Frontiers in Immunology demonstrates CIT-013’s effectiveness against additional types of extracellular traps, expanding potential therapeutic applications Oss, Netherlands – 20 February 2025 – Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), today announces the publication of new research in Frontiers in Immunology . The study demonstrates that CIT-013, originally developed to target NETs, also effectively inhibits the formation of eosinophil extracellular traps (EETs) with the same potency and verifies the presence of CIT-013’s epitope on EETs. These findings further validate Citryll’s approach and highlight the broader therapeutic potential of CIT-013 beyond inflammatory diseases that are neutrophilic in nature. CIT-013, Citryll’s first-in-class monoclonal antibody, has previously demonstrated its ability to inhibit NET formation in Phase 1 clinical trials. Extracellular traps (ETs) are web-like structures composed of DNA, histones, and antimicrobial proteins, released by cells to trap and degrade pathogens. Excessive ET formation can contribute to tissue damage and chronic inflammation in various immune-mediated inflammatory disorders. Citryll is currently investigating CIT-013 in rheumatoid arthritis (RA) and hidradenitis suppurativa (HS). This latest preclinical study highlights CIT-013’s ability to inhibit EET formation. The presence of CIT-013’s epitope on EETs will also enable binding of CIT-013 to enhance phagocytic clearance of tissue EETs, as previously established for NETs. Importantly, the study demonstrated that CIT-013’s dual mechanism of action – enhancing the clearance of existing extracellular traps and preventing the formation of new ones – applies equally to eosinophils, another type of white blood cell, reinforcing its potential as a therapy capable of targeting extracellular traps regardless of their cellular origin. The release and accumulation of EETs in inflamed tissue have been observed in multiple inflammatory diseases. These findings reinforce CIT-013’s potential to treat a broad range of ET-driven inflammatory conditions, including cardiovascular and respiratory diseases, where multiple cell types contribute to inflammation. Co-author of the publication, Professor Shigeharu Ueki, from Akita University, Japan, said: “ The discovery that CIT-013 effectively targets both NETs and EETs represents a significant advancement in the therapeutic approach to diseases with an extracellular trap pathogenesis. This could be particularly valuable in treating conditions where both neutrophil and eosinophil-mediated inflammation play important roles, and I look forward to seeing where this discovery takes us. Eric Meldrum, Chief Scientific Officer at Citryll , said: “These findings strengthen the scientific foundation of Citryll’s approach and confirm the potential of CIT-013 beyond NET driven pathologies. By demonstrating its efficacy against EETs, we are unlocking new possibilities to treat a broader range of diseases beyond RA and HS where extracellular traps drive chronic inflammation, marking an important step in validating our broader pipeline strategy.” These results follow Citryll’s recent €85 million Series B funding round , which supports the advancement of CIT-013 into Phase 2a clinical trials for RA and HS. These trials will further establish CIT-013’s unique dual mode of action, enhancing the clearance of existing NETs while preventing the formation of new ones. CIT-013 is highly selective for its epitope, minimising off-target effects, and does not enter cells, preserving normal intracellular functions. Back to news Share on social media: Other news 10-26 New research published in Frontiers in Immunology highlights CIT-013’s ability to modulate macrophage responses and promote inflammation resolution Citryll has published new preclinical research that deepens the understanding of how CIT-013, the Company’s first-in-class monoclonal antibody, modulates immune Read more 06-26 Exploring the Emerging Role of Extracellular Traps in Immune-Mediated Inflammatory Diseases Earlier this week, Citryll hosted an educational webinar bringing together leading scientific and clinical experts to discuss the evolving understanding Read more 04-26 Citryll Strengthens Intellectual Property Portfolio With Grant of European Composition of Matter Patent for CIT-013 Expected to provide exclusivity into 2039 Oss, Netherlands – 15 April 2026 – Citryll, a biotech company pioneering a transformative Read more 02-26 First patient dosed in Citryll’s imaging study evaluating distribution and target engagement of CIT-013 PET-based imaging study designed to assess the biodistribution of CIT-013 and associate disease activity with CIT-013 target disposition in participants Read more 02-26 Employee Spotlight – Catarina Antunes As a key part of Citryll’s team, Catarina Antunes, Program & Communications Manager, plays a central role in driving cross‑functional Read more 12-25 End of Year Newsletter 2025 As I look back on 2025, it has been a truly remarkable year for the Citryll team. With a laser Read more E: [email protected] Linkedin Head Office Citryll Building RK Kloosterstraat 9 5349 AB Oss The Netherlands Postal & deliveries Citryll Building OP Kloosterstraat 9 5349 AB Oss The Netherlands About Us Research & Development Therapeutic Areas Patients About Us Research & Development Therapeutic Areas Patients Publications News Careers Contact Us Publications News Careers Contact Us Latest Vacancies Contact us © Copyright the inter group (tig) | All Rights Reserved 2026 | Web Design Yorkshire Cookie Notice Privacy Policy Terms & Conditions Cookie Notice Privacy Policy Terms & Conditions About Us About Citryll Our Team Board of Directors Scientific Advisors Investors Research & Development Science of ETosis Dual Mechanism of Action Clinical Development Therapeutic Areas Rheumatoid Arthritis Hidradenitis Suppurativa Patients Publications Latest News Careers Contact Us

The release as fetched from its publisher. citryll.com ↗